1. Scrip
  2. >>Business

Will UK's IP Commercialization Model Go Trans-Atlantic Soon?

 
• By Sten Stovall

IP commercialization may be all the rage for company creation in the UK, but it remains comparatively unknown in the US. The CEOs of two Boston-based groups using that business approach – Allied Minds PLC and PureTech Health PLC – spoke to Scrip's sister publication Start-Up about their firms' strategies for creating and developing life science businesses using the model.

IP commercialization may be all the rage for company creation in the UK, but it remains comparatively unknown in the US. The CEOs of two Boston-based groups using that business approach – Allied Minds PLC and PureTech Health PLC – spoke to Scrip's sister publication Start-Up about their firms' strategies for creating and developing life science businesses using the model.

The London Stock Exchange lists about half a dozen corporations in the business of what's known as "intellectual property commercialization." These are firms that tap promising discoveries, often spun out...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Ascentage Broadens Horizons As Pipeline Shows Renewed Promise

 
• By Xu Hu

Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.

Tech Convergence, Quality Data Needed To Accelerate Korea’s AI-Powered R&D

 
• By Jung Won Shin

AI-powered drug development was a major topic at the recent Bio Korea meeting, where experts discussed how the technology is changing R&D activities and the challenges being faced by Korean firms as they look to catch up with their global competitors.

ASCO Preview: Major Solid Tumor Readouts Include AstraZeneca/Daiichi, Gilead ADCs

 
• By Alaric DeArment

Data from several closely watched solid tumor drug trials – some considered practice-changing – are scheduled for presentation at the meeting, including for AstraZeneca and Daiichi’s Enhertu.